Supply of Adequan® IM and Adequan® IA – the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses – was interrupted last year, resulting shortages in the marketplace.
Luitpold Animal Health, who manufacture these products have announced that they have been working closely with the FDA to assure that Adequan® is made available very soon, possibly the end of this month.
Last year, Luitpold renovated and upgraded its Shirley, New York manufacturing facility, which led to delays in production. The company has established www.adequan.com where consumers can register to receive future communications and updates on this matter. Information is also available at 1-800-458-0163.
More from Canadian Thoroughbred:
